Your browser doesn't support javascript.
loading
Should We Consider Deep Brain Stimulation Discontinuation in Late-Stage Parkinson's Disease?
Fabbri, Margherita; Zibetti, Maurizio; Rizzone, Mario Giorgio; Giannini, Giulia; Borellini, Linda; Stefani, Alessandro; Bove, Francesco; Bruno, Andrea; Calandra-Buonaura, Giovanna; Modugno, Nicola; Piano, Carla; Peppe, Antonella; Ardolino, Gianluca; Romagnolo, Alberto; Artusi, Carlo Alberto; Berchialla, Paola; Montanaro, Elisa; Cortelli, Pietro; Luigi, Romito; Eleopra, Roberto; Minafra, Brigida; Pacchetti, Claudio; Tufo, Tommaso; Cogiamanian, Filippo; Lopiano, Leonardo.
Afiliação
  • Fabbri M; Department of Neuroscience "Rita Levi Montalcini,", University of Torino, Turin, Italy.
  • Zibetti M; Center CIC1436, Departments of Clinical Pharmacology and Neurosciences, NS-Park/FCRIN network and NeuroToul Center of Excellence for Neurodegeneration, INSERM, University Hospital of Toulouse and University of Toulouse, Toulouse, France.
  • Rizzone MG; Department of Neurosciences, Clinical Investigation Center CIC 1436, Parkinson Toulouse Expert Center, NS-Park/FCRIN Network and NeuroToul COEN Center, Toulouse University Hospital; INSERM; University of Toulouse 3, Toulouse, France.
  • Giannini G; Department of Neuroscience "Rita Levi Montalcini,", University of Torino, Turin, Italy.
  • Borellini L; Department of Neuroscience "Rita Levi Montalcini,", University of Torino, Turin, Italy.
  • Stefani A; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
  • Bove F; Department of Biomedical and NeuroMotor Sciences (DIBINEM), Alma Mater Studiorum, University of Bologna, Bologna, Italy.
  • Bruno A; U.O. Neurofisiopatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
  • Calandra-Buonaura G; Department of System Medicine, UOSD Parkinson, University of Rome "Tor Vergata,", Rome, Italy.
  • Modugno N; U.O.C. Neurologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Piano C; IRCCS Neuromed, Pozzilli, Italy.
  • Peppe A; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
  • Ardolino G; Department of Biomedical and NeuroMotor Sciences (DIBINEM), Alma Mater Studiorum, University of Bologna, Bologna, Italy.
  • Romagnolo A; IRCCS Neuromed, Pozzilli, Italy.
  • Artusi CA; U.O.C. Neurologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Berchialla P; IRCCS Santa Lucia Foundation, Rome, Italy.
  • Montanaro E; U.O. Neurofisiopatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
  • Cortelli P; Department of Neuroscience "Rita Levi Montalcini,", University of Torino, Turin, Italy.
  • Luigi R; Department of Neuroscience "Rita Levi Montalcini,", University of Torino, Turin, Italy.
  • Eleopra R; Department of Clinical and Biological Sciences, University of Torino, Torino, Italy.
  • Minafra B; Department of Neuroscience "Rita Levi Montalcini,", University of Torino, Turin, Italy.
  • Pacchetti C; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
  • Tufo T; Department of Biomedical and NeuroMotor Sciences (DIBINEM), Alma Mater Studiorum, University of Bologna, Bologna, Italy.
  • Cogiamanian F; Department of Clinical Neurosciences, Movement Disorders Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Lopiano L; Department of Clinical Neurosciences, Movement Disorders Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Mov Disord ; 35(8): 1379-1387, 2020 08.
Article em En | MEDLINE | ID: mdl-32449542
ABSTRACT

BACKGROUND:

Subthalamic deep brain stimulation (STN-DBS) effects may decrease with Parkinson's disease (PD) progression. There is no indication if, when, and how to consider the interruption of DBS treatment in late-stage PD. The objective of the current study was to investigate the percentage of "poor stimulation responders" among late-stage PD patients for elaborating an algorithm to decide whether and when DBS discontinuation may be considered.

METHODS:

Late-stage PD patients (Hoehn Yahr stage ≥4 and Schwab and England Scale <50 in medication on/stimulation on condition) treated with STN-DBS for at least 5 years underwent a crossover, double-blind, randomized evaluation of acute effects of stimulation. Physicians, caregivers, and patients were blinded to stimulation conditions. Poor stimulation responders (MDS-UPDRS part III change <10% between stimulation on/medication off and stimulation off/medication off) maintained the stimulation off/medication on condition for 1 month for open-label assessment.

RESULTS:

Thirty-six patients were included. The acute effect of stimulation was significant (17% MDS-UPDRS part III), with 80% of patients classified as "good responders." Seven patients were classified as "poor stimulation responders," and the stimulation was switched off, but in 4 cases the stimulation was switched back "on" because of worsening of parkinsonism and dysphagia with a variable time delay (up to 10 days). No serious adverse effects occurred.

CONCLUSIONS:

The vast majority of late-stage PD patients (92%) show a meaningful response to STN-DBS. Effects of stimulation may take days to disappear after its discontinuation. We present a safe and effective decisional algorithm that could guide physicians and caregivers in making challenging therapeutic decisions in late-stage PD. © 2020 International Parkinson and Movement Disorder Society.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Núcleo Subtalâmico / Estimulação Encefálica Profunda Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Mov Disord Assunto da revista: NEUROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Núcleo Subtalâmico / Estimulação Encefálica Profunda Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Mov Disord Assunto da revista: NEUROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália